Chronic hepatitis B: A wave of new therapies on the horizon

Antiviral Research

Volumn 121, Issue , 2015, Pages 69-81

  Block, Timothy M ^a   Rawat, Siddhartha ^a   Brosgart, Carol L ^b  

^a BARUCH S BLUMBERG INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiviral therapy; Chronic hepatitis B; Clinical trials; Hepatitis B virus

Indexed keywords

AGX 1009; ANTIVIRUS AGENT; ARC 520; BESIFOVIR; BIRINAPANT; CAPSID FORMATION INHIBITOR; CYCLOPHILIN INHIBITOR; DIRECT ACTING ANTIVIRAL AGENT; DNA VACCINE; ELVUCITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAGOCICLOVIR; PRADEFOVIR; PRODRUG; RECOMBINANT VACCINE; RIBONUCLEASE H INHIBITOR; SMALL INTERFERING RNA; TENOFOVIR; TENOFOVIR 3 HEXADECYLOXYPROPYL ESTER; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VIRUS FUSION INHIBITOR; VIRUS LIKE PARTICLE VACCINE; YIC;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CLINICAL EVALUATION; CRISPR CAS SYSTEM; EPIGENETICS; HUMAN; INNATE IMMUNITY; LIVER CANCER; NONHUMAN; PRIORITY JOURNAL; VIREMIA; VIRUS CAPSID; VIRUS LIKE AGENT; VIRUS REPLICATION; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; ISOLATION AND PURIFICATION; TRENDS;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

ANIMALS; ANTIVIRAL AGENTS; DRUG DISCOVERY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS;

EID: 84935475377     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.06.014     Document Type: Review

References (146)

1. B.L. Adam, Y. Qu, J.W. Davis, M.D. Ward, M.A. Clements, L.H. Cazares, O.J. Semmes, P.F. Schellhammer, Y. Yasui, Z. Feng, and G.L. Wright Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men Cancer Res. 62 2002 3609 3614
2. N. Afdhal, K.R. Reddy, D.R. Nelson, E. Lawitz, S.C. Gordon, E. Schiff, R. Nahass, R. Ghalib, N. Gitlin, R. Herring, J. Lalezari, Z.H. Younes, P.J. Pockros, A.M. Di Bisceglie, S. Arora, G.M. Subramanian, Y. Zhu, H. Dvory-Sobol, J.C. Yang, P.S. Pang, W.T. Symonds, J.G. McHutchison, A.J. Muir, M. Sulkowski, and P. Kwo Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N. Eng. J. Med. 370 2014 1483 1493
3. P. Arends, M.J. Sonneveld, R. Zoutendijk, I. Carey, A. Brown, M. Fasano, D. Mutimer, K. Deterding, J.G. Reijnders, Y. Oo, J. Petersen, F. van Bommel, R.J. de Knegt, T. Santantonio, T. Berg, T.M. Welzel, H. Wedemeyer, M. Buti, P. Pradat, F. Zoulim, B. Hansen, and H.L. Janssen Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians Gut 2014
4. Arrowhead, 2015b. Arrowhead Provides Update on IND for ARC-520 Phase 2b Study.
5. E.J. Aspinall, G. Hawkins, A. Fraser, S.J. Hutchinson, and D. Goldberg Hepatitis B prevention, diagnosis, treatment and care: a review Occup. Med. (Lond.) 61 2011 531 540
6. P. Bedossa Reversibility of hepatitis B virus cirrhosis after therapy: who and why? Liver Int. 35 Suppl. 1 2015 78 81
7. A. Bertoletti, and A. Gehring Immune response and tolerance during chronic hepatitis B virus infection Hepatol. Res. 37 Suppl. 3 2007 S331 338
8. A. Bertoletti, and A.J. Gehring Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLoS Pathog. 9 2013 e1003784
9. A. Bertoletti, and P.T. Kennedy The immune tolerant phase of chronic HBV infection: new perspectives on an old concept Cell. Mol. Immunol. 2014
10. T.M. Block, R. Gish, H. Guo, A. Mehta, A. Cuconati, W. Thomas London, and J.T. Guo Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res. 98 2013 27 34
11. T.M. Block, H. Guo, and J.T. Guo Molecular virology of hepatitis B virus for clinicians Clin. Liver Dis. 11 2007 685 706 vii
12. T.M. Block, A.S. Mehta, C.J. Fimmel, and R. Jordan Molecular viral oncology of hepatocellular carcinoma Oncogene 22 2003 5093 5107
13. B.S. Blumberg, H.J. Alter, and S. Visnich A "New" antigen in leukemia sera JAMA: J. Am. Med. Assoc. 191 1965 541 546
14. B.S. Blumberg, B.J.S. Gerstley, D.A. Hungerford, W.T. London, and A.I. Sutnick A serum antigen (Australia antigen) in Down's Syndrome leukemia and hepatitis Ann. Int. Med. 66 1967 924 931
15. W.P. Brouwer, Q. Xie, M.J. Sonneveld, N. Zhang, Q. Zhang, F. Tabak, A. Streinu-Cercel, J.Y. Wang, R. Idilman, H.W. Reesink, M. Diculescu, K. Simon, M. Voiculescu, M. Akdogan, W. Mazur, J.G. Reijnders, E. Verhey, B.E. Hansen, and H.L. Janssen Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study) Hepatology 61 2015 1512 1522
16. C.W. Cai, E. Lomonosova, E.A. Moran, X. Cheng, K.B. Patel, F. Bailly, P. Cotelle, M.J. Meyers, and J.E. Tavis Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity Antiviral Res. 108 2014 48 55
17. D. Cai, C. Mills, W. Yu, R. Yan, C.E. Aldrich, J.R. Saputelli, W.S. Mason, X. Xu, J.T. Guo, T.M. Block, A. Cuconati, and H. Guo Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation Antimicrob. Agents Chemother. 56 2012 4277 4288
18. M.R. Campagna, F. Liu, R. Mao, C. Mills, D. Cai, F. Guo, X. Zhao, H. Ye, A. Cuconati, H. Guo, J. Chang, X. Xu, T.M. Block, and J.T. Guo Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids J. Virol. 87 2013 6931 6942
19. H.B. Chae, and H.W. Hann Time for an active antiviral therapy for hepatitis B: an update on the management of hepatitis B virus infection Ther. Clin. Risk Manag. 3 2007 605 612
20. H.L. Chan, A. Thompson, M. Martinot-Peignoux, T. Piratvisuth, M. Cornberg, M.R. Brunetto, H.L. Tillmann, J.H. Kao, J.D. Jia, H. Wedemeyer, S. Locarnini, H.L. Janssen, and P. Marcellin Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report J. Hepatol. 55 2011 1121 1131
21. J. Chang, T.M. Block, and J.T. Guo The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy Antiviral Res. 96 2012 405 413
22. T.T. Chang, R.G. Gish, R. de Man, A. Gadano, J. Sollano, Y.C. Chao, A.S. Lok, K.H. Han, Z. Goodman, J. Zhu, A. Cross, D. DeHertogh, R. Wilber, R. Colonno, and D. Apelian A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N. Eng. J. Med. 354 2006 1001 1010
23. J.Y. Cho, Y.H. Paik, W. Sohn, H.C. Cho, G.Y. Gwak, M.S. Choi, J.H. Lee, K.C. Koh, S.W. Paik, and B.C. Yoo Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease Gut 2014
24. C.S. Coffin, P.M. Mulrooney-Cousins, M.G. Peters, M.G. van, J.P. Roberts, T.I. Michalak, and N.A. Terrault Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy J. Viral Hepat. 18 2011 415 423
25. M.P. Curry, X. Forns, R.T. Chung, N.A. Terrault, R. Brown Jr., J.M. Fenkel, F. Gordon, J. O'Leary, A. Kuo, T. Schiano, G. Everson, E. Schiff, A. Befeler, E. Gane, S. Saab, J.G. McHutchison, G.M. Subramanian, W.T. Symonds, J. Denning, L. McNair, S. Arterburn, E. Svarovskaia, D. Moonka, and N. Afdhal Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study Gastroenterology 148 100-107 2015 e101
26. C.L. Day, D.E. Kaufmann, P. Kiepiela, J.A. Brown, E.S. Moodley, S. Reddy, E.W. Mackey, J.D. Miller, A.J. Leslie, C. DePierres, Z. Mncube, J. Duraiswamy, B. Zhu, Q. Eichbaum, M. Altfeld, E.J. Wherry, H.M. Coovadia, P.J. Goulder, P. Klenerman, R. Ahmed, G.J. Freeman, and B.D. Walker PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression Nature 443 2006 350 354
27. K. Deres, C.H. Schroder, A. Paessens, S. Goldmann, H.J. Hacker, O. Weber, T. Kramer, U. Niewohner, U. Pleiss, J. Stoltefuss, E. Graef, D. Koletzki, R.N. Masantschek, A. Reimann, R. Jaeger, R. Gross, B. Beckermann, K.H. Schlemmer, D. Haebich, and H. Rubsamen-Waigmann Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids Science 299 2003 893 896
28. C. Dong, L. Qu, H. Wang, L. Wei, Y. Dong, and S. Xiong Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication Antiviral Res. 118 2015 110 117
29. A.M. Dougherty, H. Guo, G. Westby, Y. Liu, E. Simsek, J.T. Guo, A. Mehta, P. Norton, B. Gu, T. Block, and A. Cuconati A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion Antimicrob. Agents Chemother. 51 2007 4427 4437
30. EASL EASL clinical practice guidelines: management of chronic hepatitis B virus infection J. Hepatol. 57 2012 167 185
31. G. Ebert, C. Allison, S. Preston, J. Cooney, J.G. Toe, M.D. Stutz, S. Ojaimi, N. Baschuk, U. Nachbur, J. Torresi, J. Silke, C.G. Begley, and M. Pellegrini Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis Proc. Natl. Acad. Sci. U.S.A. 2015
32. G. Ebert, S. Preston, C. Allison, J. Cooney, J.G. Toe, M.D. Stutz, S. Ojaimi, H.W. Scott, N. Baschuk, U. Nachbur, J. Torresi, R. Chin, D. Colledge, X. Li, N. Warner, P. Revill, S. Bowden, J. Silke, C.G. Begley, and M. Pellegrini Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus Proc. Natl. Acad. Sci. U.S.A. 2015
33. H.B. El-Serag Epidemiology of viral hepatitis and hepatocellular carcinoma Gastroenterology 142 1264-1273 2012 e1261
34. H.B. El-Serag, and K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2007 2557 2576
35. A. Gaggar, C. Coeshott, D. Apelian, T. Rodell, B.R. Armstrong, G. Shen, G.M. Subramanian, and J.G. McHutchison Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study Vaccine 32 2014 4925 4931
36. E.J. Gane, Y.S. Lim, S.C. Gordon, K. Visvanathan, E. Sicard, R.N. Fedorak, S. Roberts, B. Massetto, Z. Ye, S. Pflanz, K.L. Garrison, A. Gaggar, G. Mani Subramanian, J.G. McHutchison, S. Kottilil, B. Freilich, C.S. Coffin, W. Cheng, and Y.J. Kim The oral Toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection J. Hepatol. 2015
37. D. Ganem, and A.M. Prince Hepatitis B virus infection-natural history and clinical consequences N. Eng. J. Med. 350 2004 1118 1129
38. D. Gardiner, J. Lalezari, E. Lawitz, M. DiMicco, R. Ghalib, K.R. Reddy, K.M. Chang, M. Sulkowski, S.O. Marro, J. Anderson, B. He, V. Kansra, F. McPhee, M. Wind-Rotolo, D. Grasela, M. Selby, A.J. Korman, and I. Lowy A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection PLoS ONE 8 2013 e63818
39. George, R., 2014. Chimigen® HBV therapeutic vaccine: a novel dendritic cell receptor-targeted immunotherapy for treating chronic Hepatitis B virus infection, $th World Congress on Virology, HIlton San Antonio Airport, TX, USA.
40. R.G. Gish, J.A. Marrero, and A.B. Benson A multidisciplinary approach to the management of hepatocellular carcinoma Gastroenterol. Hepatol. 6 2010 1 16
41. S.C. Gordon, L.E. Lamerato, L.B. Rupp, J. Li, S.D. Holmberg, A.C. Moorman, P.R. Spradling, E.H. Teshale, V. Vijayadeva, J.A. Boscarino, E.M. Henkle, N. Oja-Tebbe, and M. Lu Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population Clin. Gastroenterol. Hepatol. 12 2014 885 893
42. P. Gripon, I. Cannie, and S. Urban Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein J. Virol. 79 2005 1613 1622
43. Grogan, K., 2013. Medivir and Daewoong pull plug on hepatitis B drug. PharmaTimes Digital.
44. F. Guo, Y. Han, X. Zhao, J. Wang, F. Liu, C. Xu, L. Wei, J.D. Jiang, T.M. Block, J.T. Guo, and J. Chang STING agonists induce an innate antiviral immune response against hepatitis B virus Antimicrob. Agents Chemother. 59 2015 1273 1281
45. S.A. Halperin, S. Dobson, S. McNeil, J.M. Langley, B. Smith, R. McCall-Sani, D. Levitt, G.V. Nest, D. Gennevois, and J.J. Eiden Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults Vaccine 24 2006 20 26
46. C. Holohan, S. Van Schaeybroeck, D.B. Longley, and P.G. Johnston Cancer drug resistance: an evolving paradigm Nat. Rev. Cancer 13 2013 714 726
47. J.H. Hoofnagle Reactivation of hepatitis B Hepatology 49 2009 S156 165
48. J.H. Hoofnagle, E. Doo, T.J. Liang, R. Fleischer, and A.S. Lok Management of hepatitis B: summary of a clinical research workshop Hepatology 45 2007 1056 1075
49. J.H. Hoofnagle, and A.H. Sherker Therapy for hepatitis C - the costs of success N. Eng. J. Med. 370 2014 1552 1553
50. K.Y. Hostetler Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art Antiviral Res. 82 2009 A84 98
51. J. Jaroszewicz, B. Calle Serrano, K. Wursthorn, K. Deterding, J. Schlue, R. Raupach, R. Flisiak, C.T. Bock, M.P. Manns, H. Wedemeyer, and M. Cornberg Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective J. Hepatol. 52 2010 514 522
52. F. Kanwal, H.B. El-Serag, and D. Ross Surveillance for hepatocellular carcinoma: can we focus on the mission? Clin. Gastroenterol. Hepatol. 13 2015 805 807
53. S.P. Katen, Z. Tan, S.R. Chirapu, M.G. Finn, and A. Zlotnick Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure Structure 21 2013 1406 1416
54. E.M. Kennedy, L.C. Bassit, H. Mueller, A.V. Kornepati, H.P. Bogerd, T. Nie, P. Chatterjee, H. Javanbakht, R.F. Schinazi, and B.R. Cullen Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease Virology 476 2015 196 205
55. O. Khan, and N.B. La Thangue HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications Immunol. Cell Biol. 90 2012 85 94
56. B.H. Kim, Y.J. Lee, W. Kim, J.H. Yoon, E.U. Jung, S.J. Park, Y.J. Kim, and H.S. Lee Efficacy of thymosin alpha-1 plus peginterferon alpha-2a combination therapy compared with peginterferon alpha-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study Scand. J. Gastroenterol. 47 2012 1048 1055
57. K.V. Kowdley, S.C. Gordon, K.R. Reddy, L. Rossaro, D.E. Bernstein, E. Lawitz, M.L. Shiffman, E. Schiff, R. Ghalib, M. Ryan, V. Rustgi, M. Chojkier, R. Herring, A.M. Di Bisceglie, P.J. Pockros, G.M. Subramanian, D. An, E. Svarovskaia, R.H. Hyland, P.S. Pang, W.T. Symonds, J.G. McHutchison, A.J. Muir, D. Pound, and M.W. Fried Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N. Eng. J. Med. 370 2014 1879 1888
58. R.E. Lanford, B. Guerra, D. Chavez, L. Giavedoni, V.L. Hodara, K.M. Brasky, A. Fosdick, C.R. Frey, J. Zheng, G. Wolfgang, R.L. Halcomb, and D.B. Tumas GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees Gastroenterology 144 2013 1508 1517 1517 e1501-1510
59. G.K. Lau, T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, G. Cooksley, E. Gane, M.W. Fried, W.C. Chow, S.W. Paik, W.Y. Chang, T. Berg, R. Flisiak, P. McCloud, and N. Pluck Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N. Eng. J. Med. 352 2005 2682 2695
60. H.W. Lee, J.I. Lee, S.H. Um, S.H. Ahn, H.Y. Chang, Y.K. Park, S.P. Hong, Y.M. Moon, and K.H. Han Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: a prospective randomized, comparative pilot study J. Gastroenterol. Hepatol. 23 2008 729 735
61. Y.B. Lee, J.H. Lee, W.M. Choi, Y.Y. Cho, J.J. Yoo, M. Lee, D.H. Lee, Y. Cho, S.J. Yu, Y.J. Kim, J.H. Yoon, C.Y. Kim, and H.S. Lee Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection Antimicrob. Agents Chemother. 57 2013 6325 6332
62. L. Liaw, and H.C. Crawford Functions of the extracellular matrix and matrix degrading proteases during tumor progression Braz. J. Med. Biol. Res. 32 1999 805 812
63. Y.F. Liaw, J.H. Kao, T. Piratvisuth, H.L.Y. Chan, R.N. Chien, C.J. Liu, E. Gane, S. Locarnini, S.G. Lim, K.H. Han, D. Amarapurkar, G. Cooksley, W. Jafri, R. Mohamed, J.L. Hou, W.L. Chuang, L.A. Lesmana, J.D. Sollano, D.J. Suh, and M. Omata Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update Hep. Intl. 6 2012 531 561
64. Y.F. Liaw, N. Leung, J.H. Kao, T. Piratvisuth, E. Gane, K.H. Han, R. Guan, G.K. Lau, and S. Locarnini Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol. Int. 2 2008 263 283
65. Y.F. Liaw, J.J. Sung, W.C. Chow, G. Farrell, C.Z. Lee, H. Yuen, T. Tanwandee, Q.M. Tao, K. Shue, O.N. Keene, J.S. Dixon, D.F. Gray, and J. Sabbat Lamivudine for patients with chronic hepatitis B and advanced liver disease N. Eng. J. Med. 351 2004 1521 1531
66. S.R. Lin, H.C. Yang, Y.T. Kuo, C.J. Liu, T.Y. Yang, K.C. Sung, Y.Y. Lin, H.Y. Wang, C.C. Wang, Y.C. Shen, F.Y. Wu, J.H. Kao, D.S. Chen, and P.J. Chen The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Molecular therapy Nucleic Acids 3 2014 e186
67. F. Liu, M. Campagna, Y. Qi, X. Zhao, F. Guo, C. Xu, S. Li, W. Li, T.M. Block, J. Chang, and J.T. Guo Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes PLoS Pathog. 9 2013 e1003613
68. M.A. Lobritz, A.N. Ratcliff, and E.J. Arts HIV-1 entry, inhibitors, and resistance Viruses 2 2010 1069 1105
69. Locarnini, S., 2004. Molecular virology of hepatitis B virus.
70. A.S. Lok Prevention of hepatitis B virus-related hepatocellular carcinoma Gastroenterology 127 2004 S303 309
71. A.S. Lok Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? J. Gastroenterol. Hepatol. 26 2011 221 227
72. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
73. A.S. Lok, J.W. Ward, R.P. Perrillo, B.J. McMahon, and T.J. Liang Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable Ann. Intern. Med. 156 2012 743 745
74. Mahtab MA, B.M., Vaillant A, 2015. Effects of nucleic acid polymer therapy alone or in combination with immunotherapy on the establishment of SVR in patients with chronic HBV infection.
75. R. Mao, J. Zhang, D. Jiang, D. Cai, J.M. Levy, A. Cuconati, T.M. Block, J.T. Guo, and H. Guo Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells J. Virol. 85 2011 1048 1057
76. F.E. Membreno, J.C. Espinales, and E.J. Lawitz Cyclophilin inhibitors for hepatitis C therapy Clin. Liver Dis. 17 2013 129 139
77. L. Menendez-Arias, M. Alvarez, and B. Pacheco Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance Curr. Opin. Virol. 8 2014 1 9
78. T.I. Michalak, H. Zhang, N.D. Churchill, T. Larsson, N.G. Johansson, and B. Oberg Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B Antimicrob. Agents Chemother. 53 2009 3803 3814
79. M.L. Michel, M. Bourgine, H. Fontaine, and S. Pol Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end? Med. Microbiol. Immunol. 204 2015 121 129
80. S. Nkongolo, Y. Ni, F.A. Lempp, C. Kaufman, T. Lindner, K. Esser-Nobis, V. Lohmann, W. Mier, S. Mehrle, and S. Urban Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor J. Hepatol. 60 2014 723 731
81. F. Noordeen, A. Vaillant, and A.R. Jilbert Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro Antimicrob. Agents Chemother. 57 2013 5291 5298
82. P.A. Norton, S. Menne, G. Sinnathamby, L. Betesh, P.J. Cote, R. Philip, A.S. Mehta, B.C. Tennant, and T.M. Block Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks Hepatology 52 2010 1242 1250
83. A.K. O'Neill, M.J. Niederst, and A.C. Newton Suppression of survival signalling pathways by the phosphatase PHLPP FEBS J. 280 2013 572 583
84. N. Obeng-Adjei, D.K. Choo, J. Saini, J. Yan, P. Pankhong, A. Parikh, J.S. Chu, and D.B. Weiner Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver Cancer Gene Ther. 19 2012 779 787
85. G.R. Painter, M.R. Almond, L.C. Trost, B.M. Lampert, J. Neyts, E. De Clercq, B.E. Korba, K.A. Aldern, J.R. Beadle, and K.Y. Hostetler Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections Antimicrob. Agents Chemother. 51 2007 3505 3509
86. J.M. Pawlotsky New hepatitis C therapies: the toolbox, strategies, and challenges Gastroenterology 146 2014 1176 1192
87. A.M. Pellicelli, G. Barbaro, R. Francavilla, M. Romano, G. Barbarini, E. Mazzoni, F. Mecenate, A. Paffetti, A. Barlattani, C. Struglia, R. Villani, L. Nauri, L. Nosotti, O. Armignacco, F. Ferri, M.P. Camporiondo, and F. Soccorsi Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study Clin. Ther. 30 2008 317 323
88. G. Peng, S. Li, W. Wu, X. Tan, Y. Chen, and Z. Chen PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients Mol. Immunol. 45 2008 963 970
89. M.G. Peters, H. Hann Hw, P. Martin, E.J. Heathcote, P. Buggisch, R. Rubin, M. Bourliere, K. Kowdley, C. Trepo, D. Gray Df, M. Sullivan, K. Kleber, R. Ebrahimi, S. Xiong, and C.L. Brosgart Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 2004 91 101
90. J. Petersen, M. Dandri, W. Mier, M. Lutgehetmann, T. Volz, F. von Weizsacker, U. Haberkorn, L. Fischer, J.M. Pollok, B. Erbes, S. Seitz, and S. Urban Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein Nat. Biotechnol. 26 2008 335 341
91. S. Phillips, S. Chokshi, U. Chatterji, A. Riva, M. Bobardt, R. Williams, P. Gallay, and N.V. Naoumov Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production Gastroenterology 148 403-414 2015 e407
92. S.A. Plotkin, and W. Schaffner A hepatitis B vaccine with a novel adjuvant Vaccine 31 2013 5297 5299
93. K.R. Reddy, M.C. Matelich, B.G. Ugarkar, J.E. Gomez-Galeno, J. DaRe, K. Ollis, Z. Sun, W. Craigo, T.J. Colby, J.M. Fujitaki, S.H. Boyer, P.D. van Poelje, and M.D. Erion Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B J. Med. Chem. 51 2008 666 676
94. P.A. Roethle, R.M. McFadden, H. Yang, P. Hrvatin, H. Hui, M. Graupe, B. Gallagher, J. Chao, J. Hesselgesser, P. Duatschek, J. Zheng, B. Lu, D.B. Tumas, J. Perry, and R.L. Halcomb Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis J. Med. Chem. 56 2013 7324 7333
95. M. Saruc, N. Ozden, N. Turkel, S. Ayhan, L.M. Hock, I. Tuzcuoglu, and H. Yuceyar Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B J. Pharm. Sci. 92 2003 1386 1395
96. S. Sato, K. Li, T. Kameyama, T. Hayashi, Y. Ishida, S. Murakami, T. Watanabe, S. Iijima, Y. Sakurai, K. Watashi, S. Tsutsumi, Y. Sato, H. Akita, T. Wakita, C.M. Rice, H. Harashima, M. Kohara, Y. Tanaka, and A. Takaoka The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus Immunity 42 2015 123 132
97. J.H. Schickli, D.C. Whitacre, R.S. Tang, J. Kaur, H. Lawlor, C.J. Peters, J.E. Jones, D.L. Peterson, M.P. McCarthy, G. Van Nest, and D.R. Milich Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge J. Clin. Investig. 125 2015 1637 1647
98. C. Seeger, and W.S. Mason Hepatitis B virus biology Microbiol. Mol. Biol. Rev. 64 2000 51 68
99. C. Seeger, and J.A. Sohn Targeting hepatitis B virus with CRISPR/Cas9. Molecular therapy Nucleic Acids 3 2014 e216
100. B.A. Seigal, W.H. Connors, A. Fraley, R.M. Borzilleri, P.H. Carter, S.L. Emanuel, J. Fargnoli, K. Kim, M. Lei, J.G. Naglich, M.E. Pokross, S.L. Posy, H. Shen, N. Surti, R. Talbott, Y. Zhang, and N.K. Terrett The discovery of macrocyclic XIAP antagonists from a DNA-programmed chemistry library, and their optimization to give lead compounds with in vivo antitumor activity J. Med. Chem. 58 2015 2855 2861
101. W.K. Seto, T.S. Chan, Y.Y. Hwang, D.K. Wong, J. Fung, K.S. Liu, H. Gill, Y.F. Lam, A.K. Lie, C.L. Lai, Y.L. Kwong, and M.F. Yuen Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study J. Clin. Oncol. 32 2014 3736 3743
102. E. Simsek, G. Sinnathamby, T.M. Block, Y. Liu, R. Philip, A.S. Mehta, and P.A. Norton Inhibition of cellular alpha-glucosidases results in increased presentation of hepatitis B virus glycoprotein-derived peptides by MHC class I Virology 384 2009 12 15
103. D.A. Smith Do prodrugs deliver? Curr. Opin. Drug Discov. Devel. 10 2007 550 559
104. Springbank, SB 9200 HCV. Spring Bank Parmaceuticals.
105. S.J. Stray, C.R. Bourne, S. Punna, W.G. Lewis, M.G. Finn, and A. Zlotnick A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly Proc. Natl. Acad. Sci. U.S.A. 102 2005 8138 8143
106. S.J. Stray, and A. Zlotnick BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly J. Mol. Recognit. 19 2006 542 548
107. J.E. Tavis, and E. Lomonosova The hepatitis B virus ribonuclease H as a drug target Antiviral Res. 118 2015 132 138
108. S.L. Tsai, I.S. Sheen, R.N. Chien, C.M. Chu, H.C. Huang, Y.L. Chuang, T.H. Lee, S.K. Liao, C.L. Lin, G.C. Kuo, and Y.F. Liaw Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications J. Biomed. Sci. 10 2003 120 135
109. H.T. Tzeng, H.F. Tsai, H.J. Liao, Y.J. Lin, L. Chen, P.J. Chen, and P.N. Hsu PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model PLoS ONE 7 2012 e39179
110. S. Urban, R. Bartenschlager, R. Kubitz, and F. Zoulim Strategies to inhibit entry of HBV and HDV into hepatocytes Gastroenterology 147 2014 48 64
111. L.A. Uribe, C.G. O'Brien, R.J. Wong, R.R. Gish, N. Tsai, and M.H. Nguyen Current treatment guidelines for chronic hepatitis B and their applications J. Clin. Gastroenterol. 48 2014 773 783
112. X.Y. Wang, Z.M. Wei, G.Y. Wu, J.H. Wang, Y.J. Zhang, J. Li, H.H. Zhang, X.W. Xie, X. Wang, Z.H. Wang, L. Wei, Y. Wang, and H.S. Chen In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations Antivir. Ther. 17 2012 793 803
113. J.W. Ward Hepatitis C virus: the 25-year journey from discovery to cure Hepatology 60 2014 1479 1482
114. O. Weber, K.H. Schlemmer, E. Hartmann, I. Hagelschuer, A. Paessens, E. Graef, K. Deres, S. Goldmann, U. Niewoehner, J. Stoltefuss, D. Haebich, H. Ruebsamen-Waigmann, and S. Wohlfeil Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model Antiviral Res. 54 2002 69 78
115. B. Werle-Lapostolle, S. Bowden, S. Locarnini, K. Wursthorn, J. Petersen, G. Lau, C. Trepo, P. Marcellin, Z. Goodman, W.E.t. Delaney, S. Xiong, C.L. Brosgart, S.S. Chen, C.S. Gibbs, and F. Zoulim Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 2004 1750 1758
116. A.C. West, and R.W. Johnstone New and emerging HDAC inhibitors for cancer treatment J. Clin. Investig. 124 2014 30 39
117. D.C. Whitacre, B.O. Lee, and D.R. Milich Use of hepadnavirus core proteins as vaccine platforms Expert Rev. Vaccines 8 2009 1565 1573
118. C.I. Wooddell, D.B. Rozema, M. Hossbach, M. John, H.L. Hamilton, Q. Chu, J.O. Hegge, J.J. Klein, D.H. Wakefield, C.E. Oropeza, J. Deckert, I. Roehl, K. Jahn-Hofmann, P. Hadwiger, H.P. Vornlocher, A. McLachlan, and D.L. Lewis Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection Mol. Ther. 21 2013 973 985
119. G. Wu, B. Liu, Y. Zhang, J. Li, A. Arzumanyan, M.M. Clayton, R.F. Schinazi, Z. Wang, S. Goldmann, Q. Ren, F. Zhang, and M.A. Feitelson Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly Antimicrob. Agents Chemother. 57 2013 5344 5354
120. X. Wu, J. Jia, and H. You Thymosin alpha-1 treatment in chronic hepatitis B Expert Opin. Biol. Ther. 2015 1 4
121. Y. Xing, and K.A. Hogquist T-cell tolerance: central and peripheral Cold Spring Harb. Perspect. Biol. 4 2012
122. D.Z. Xu, X.Y. Wang, X.L. Shen, G.Z. Gong, H. Ren, L.M. Guo, A.M. Sun, M. Xu, L.J. Li, X.H. Guo, Z. Zhen, H.F. Wang, H.Y. Gong, C. Xu, N. Jiang, C. Pan, Z.J. Gong, J.M. Zhang, J. Shang, J. Xu, Q. Xie, T.F. Wu, W.X. Huang, Y.G. Li, J. Xu, Z.H. Yuan, B. Wang, K. Zhao, and Y.M. Wen Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings J. Hepatol. 59 2013 450 456
123. D.Z. Xu, K. Zhao, L.M. Guo, L.J. Li, Q. Xie, H. Ren, J.M. Zhang, M. Xu, H.F. Wang, W.X. Huang, X.F. Bai, J.Q. Niu, P. Liu, X.Y. Chen, X.L. Shen, Z.H. Yuan, X.Y. Wang, and Y.M. Wen A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients PLoS ONE 3 2008 e2565
124. Y. Xu, Y. Hu, B. Shi, X. Zhang, J. Wang, Z. Zhang, F. Shen, Q. Zhang, S. Sun, and Z. Yuan HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells Mol. Immunol. 46 2009 2640 2646
125. H.J. Yang, J.H. Lee, Y.J. Kim, J.H. Yoon, and H.S. Lee Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance J. Med. Virol. 84 2012 424 430
126. Y.F. Yang, W. Zhao, Y.D. Zhong, Y.J. Yang, L. Shen, N. Zhang, and P. Huang Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis Antiviral Res. 77 2008 136 141
127. S. Yapali, N. Talaat, and A.S. Lok Management of hepatitis B: our practice and how it relates to the guidelines Clin. Gastroenterol. Hepatol. 12 2014 16 26
128. J. You, L. Zhuang, B.Z. Tang, W.B. Yang, S.Y. Ding, W. Li, R.X. Wu, H.L. Zhang, Y.M. Zhang, S.M. Yan, and L. Zhang A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B World J. Gastroenterol. 7 2001 411 414
129. W. Yu, C. Goddard, E. Clearfield, C. Mills, T. Xiao, H. Guo, J.D. Morrey, N.E. Motter, K. Zhao, T.M. Block, A. Cuconati, and X. Xu Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion J. Med. Chem. 54 2011 5660 5670
130. M.F. Yuen, K.H. Han, S.H. Um, S.K. Yoon, H.R. Kim, J. Kim, C.R. Kim, and C.L. Lai Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease Hepatology 51 2010 767 776
131. M.F. Yuen, and C.L. Lai Treatment of chronic hepatitis B: Evolution over two decades J. Gastroenterol. Hepatol. 26 Suppl. 1 2011 138 143
132. M.B. Zeisel, J. Lucifora, W.S. Mason, C. Sureau, J. Beck, M. Levrero, M. Kann, P.A. Knolle, M. Benkirane, D. Durantel, M.L. Michel, B. Autran, F.L. Cosset, H. Strick-Marchand, C. Trepo, J.H. Kao, F. Carrat, K. Lacombe, R.F. Schinazi, F. Barre-Sinoussi, J.F. Delfraissy, and F. Zoulim Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure Gut 2015
133. W.J. Zhang, C.H. Peng, and S.S. Zheng Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B Hepatobiliary Pancreat. Dis. Int. 12 2013 394 399
134. F. Zoulim, and D. Durantel Antiviral therapies and prospects for a cure of chronic hepatitis B Cold Spring Harb. Perspect. Med. 5 2015
135. F. Zoulim, and S. Locarnini Hepatitis B virus resistance to nucleos(t)ide analogues Gastroenterology 137 1593-1608 2009 e1591 1592
136. Achillion Pharmaceuticals, I., 2010. < http://ir.achillion.com/releasedetail.cfm?releaseid=441884 >.
137. Alnylam, 2014. Alnylam Announces New RNAi Therapeutic Program for the Treatment of Hepatitis B Virus (HBV) Infection and Reports an Up to 2.3 Log10 Reduction of HBV Surface Antigen (HBsAg) in Chronically Infected Chimpanzees. < http://investors.alnylam.com/releasedetail.cfm?ReleaseID=847055 >.
138. Altravax, Hepatitis B Virus (HBV) vaccine. < http://www.altravax.com/?page-id=108 >.
139. Arrowhead, 2015a. Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520. < http://ir.arrowheadresearch.com/releasedetail.cfm?releaseid=906108 >.
140. Benitech Biopharma. Hepatitis B. < http://www.benitec.com/pipeline/in-house-programs-detail#hepb >.
141. Contravir, CMX157 Overview. < http://contravir.com/cmx157/ >.
142. DYNAVAX, 2011. Dynavax Reports Additional Positive Phase 1B Immunogenicity Data for Hepatitis B Therapy Candidate. < http://investors.dynavax.com/releasedetail.cfm?releaseid=551782 >.
143. HEC. < http://www.hecpharm.com/research-and-development/pipeline.html#.VWiowyj9vKM >.
144. Hepatera, 2014. Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic Hepatitis B and Delta, PR Newswire. < http://www.prnewswire.com/news-releases/maxwell-biotech-portfolio-company-hepatera-announces-proof-of-concept-clinical-results-with-myrcludex-b-a-novel-entry-inhibitor-for-treatment-of-chronic-hepatitis-b-and-delta-279878112.html >.
145. Inovio, 2015. INO-1800 SynCon® immunotherapy for hepatitis B virus. < http://www.inovio.com/products/infectious-disease-vaccines/hepatitis/hbv/ >.
146. TetraLogic, Birinapant. < http://tetralogicpharma.com/birinapant/ >.